JUMP REPORT
| Avg Daily Volume: 8,794,463 Market Cap: 417.32M Sector: Services Short Interest: 20.81 |
EARNINGS EXPECTATIONS:
THIS QTR: EPS: -.07/share REV: 5,380/M
___________________________________________________________
LAST QTR: EPS: -.35/share ACTUAL: -.20/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: ..01/share REV: 5,390/M
______________________________________________________
FULL YR: EPS: -.02/share REV: 21,590/M
______________________________________________________
*These are the base metrics we will be watching against the actual release numbers
______________________________________________________
BEAT/MISS HISTORY: 35% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) -14.03, 13.58, 3.90
POTENTIAL JUMP MOVE: 12-15%
Links To Latest News and Headlines
Solid performance in PBM and Elixir along with expanded omnichannel services is expected to have aided Rite Aid’s (RAD) Q4 revenues. However, COVID-19 woes remain concerns.
In this episode of MarketFoolery, host Chris Hill and Motley Fool analyst Bill Barker discuss how RH (NYSE: RH) sold a lot of luxury furniture in the fourth quarter, wrapping up a great fiscal year. Also, KB Home (NYSE: KBH) shares fell despite strong first-quarter profits, and Rite Aid (NYSE: RAD) updated guidance (which sent the stock down 20%). To catch full episodes of all The Motley Fool’s free podcasts, check out our podcast center.
Shares of Rite Aid (NYSE: RAD) fell 20% Thursday after the drugstore chain cut its full-year financial outlook. Coronavirus-related social distancing measures have weighed on Rite Aid’s revenue and profits. “During the fourth quarter our industry was impacted by a historically soft cough, cold, and flu season, as well as the continued impacts of COVID on the deferral of elective procedures and related acute prescription volume,” CEO Heyward Donigan said in a press release.
Cold-remedy sales have slumped because of Covid-19 guidelines, but vaccinations now and the possibility of boosters later brighten the outlook.
Rite Aid stock is trying to settle below the $18 level.
Analysis and trade direction are uploaded generally between noon and 1pm EST for most events. ALWAYS check back near market close for updates as the analysis can change by end of session.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
This area reserved for subscribers to the Options Intelligence Strategy. If this is something you wish to participate in, just let us know below.
NOTE: There is a significant amount of data behind the scenes in getting to the analysis in the tab above. Too much information for traders only confuses things – so this is striped down to only what it needed to make the best possible decision(s) on trading the trajectory.
NOTICE: All data on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.